Javascript must be enabled to continue!
Declaration for Open Science and Research 2025—2030
View through CrossRef
The Declaration for Open Science and Research 2025–2030 is an update to the previous Declaration for Open Science and Research 2020–2025. The declaration is elaborated in more detail by four national open science policies, which further define and explain the concepts used in the declaration.
The operating environment of open science is constantly changing, which is why the contents of the declaration also need to be assessed and updated regularly. This version of the declaration considers especially the rapidly changed geopolitical environment and the resulting security concerns. Even though the world is undergoing upheaval, trust in scientific collaboration and openness remains a valuable part of a safe global community built on trust.
The Declaration for Open Science and Research 2025–2030 is the result of collaborative development within the research community. Experts working under the national Open Science Coordination and key stakeholders across the research sector contributed to its drafting. The declaration was officially adopted by the National Open Science and Research Steering Group on 24 March 2025. With the updated declaration, Finland reaffirms its role as an international forerunner in open science – together and responsibly.
Tieteellisten seurain valtuuskunta
Title: Declaration for Open Science and Research 2025—2030
Description:
The Declaration for Open Science and Research 2025–2030 is an update to the previous Declaration for Open Science and Research 2020–2025.
The declaration is elaborated in more detail by four national open science policies, which further define and explain the concepts used in the declaration.
The operating environment of open science is constantly changing, which is why the contents of the declaration also need to be assessed and updated regularly.
This version of the declaration considers especially the rapidly changed geopolitical environment and the resulting security concerns.
Even though the world is undergoing upheaval, trust in scientific collaboration and openness remains a valuable part of a safe global community built on trust.
The Declaration for Open Science and Research 2025–2030 is the result of collaborative development within the research community.
Experts working under the national Open Science Coordination and key stakeholders across the research sector contributed to its drafting.
The declaration was officially adopted by the National Open Science and Research Steering Group on 24 March 2025.
With the updated declaration, Finland reaffirms its role as an international forerunner in open science – together and responsibly.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Perspectives d'exportation de GNL et d'hydrogène de l'Afrique subsaharienne vers l'UE (Prospects for LNG and Hydrogen Export from Sub-Saharan Africa to the EU)
Perspectives d'exportation de GNL et d'hydrogène de l'Afrique subsaharienne vers l'UE (Prospects for LNG and Hydrogen Export from Sub-Saharan Africa to the EU)
<b>English abstract:</b> Since Russia's war in Ukraine, many European countries have been scrambling to find alternative energy sources. One of the answers was to incre...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Abstract PS7-09: Achievability of 2030 sustainable development goals in breast cancer control
Abstract PS7-09: Achievability of 2030 sustainable development goals in breast cancer control
Abstract
Background
The United Nations Sustainable Development Goals (SDGs) target a one-third reduction in non-communicable disease (NCD) mortality b...
The revision of the Declaration of Helsinki: past, present and future
The revision of the Declaration of Helsinki: past, present and future
The World Medical Association's Declaration of Helsinki was first adopted in 1964. In its 40‐year lifetime the Declaration has been revised five times and has risen to a position o...
The Burden of Road Traffic Injuries: A Global Perspective
The Burden of Road Traffic Injuries: A Global Perspective
Introduction Road Traffic Injury (RTI) pose a significant health challenge. It represents the eighth leading cause of death globally, prompting the UN to designate 2011-2020 as...

